• 1
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980; 302: 9817.
  • 2
    Stack WA, Williams D, Stevenson M, Logan RF. Immunosuppressive therapy for ulcerative colitis: results of a nation-wide survey among consultant physician members of the British Society of Gastroenterology. Aliment Pharmacol Ther 1991; 13: 56975.DOI: 10.1046/j.1365-2036.1999.00511.x
  • 3
    Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992; 305: 202.
  • 4
    Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a 5-year experience. Am J Gastroenterol 1999; 94: 158792.
    Direct Link:
  • 5
    Marion JF & Present DH. Modern medical treatment of severe acute ulcerative colitis. Eur J Gastroenterol Hepatol 1997; 9: 8315.
  • 6
    Actis GC, Pinna-Pintor M, Rizzetto M. Azathioprine to maintain the response of acute ulcerative colitis to cyclosporin. Gastroenterology 1998; 114: G3760G3760.
  • 7
    Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft-gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflammatory Bowel Dis 1998; 4: 2769.
  • 8
    Pinna-Pintor M, Arese P, Bona R, et al. Severe steroid-unresponsive ulcerative colitis (outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment). Dis Colon Rectum 2000; 43: 60914.
  • 9
    Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 1989; 111: 6419.
  • 10
    Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley & Sons, 1981.
  • 11
    Present DH. Interaction of 6MP and azathioprine with 5-ASA agents. Gastroenterology 2000;119: 276276>.
  • 12
    Lichtiger S & Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336: 169.
  • 13
    Gurudu SR, Griffel LH, Gialanella RJ, Das KM. Cyclosporine therapy in inflammatory bowel disease: short and long-term results. J Clin Gastroenterol 1999; 29: 1513.
  • 14
    Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease. 27 years of experience Gut 1993; 34: 10815.
  • 15
    George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 17114.
  • 16
    Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-MP. Lancet 1996; 347: 2159.
  • 17
    Modigliani R. Immunosuppressors for inflammatory bowel disease: how long is long enough? Inflammatory Bowel Dis 2000; 6: 2517.
  • 18
    Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 81321.
  • 19
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necosis factor antibody to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 7619.
  • 20
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. New Engl J Med 1999; 340: 1398405.